Synergistic effect of Toll-like receptor 4 and 7/8 agonists is necessary to generate potent blast-derived dendritic cells in Acute Myeloid Leukemia

Leukemia Research

Volumn 36, Issue 9, 2012, Pages 1193-1199

  Nourizadeh, Maryam ^a,b   Masoumi, Farimah ^b   Memarian, Ali ^a   Alimoghaddam, Kamran ^c   Moazzeni, Seyed Mohammad ^d   Hadjati, Jamshid ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Acute Myeloid Leukemia (AML); Dendritic cell; TLR agonists

Indexed keywords

CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; T6 ANTIGEN; TOLL LIKE RECEPTOR 4 AGONIST; TOLL LIKE RECEPTOR 7 AGONIST; TOLL LIKE RECEPTOR 8 AGONIST; TOLL LIKE RECEPTOR AGONIST; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNOTHERAPY; CELL COUNT; CELL DIFFERENTIATION; CELL DIVISION; CELL MATURATION; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DENDRITIC CELL; FEMALE; HUMAN; HUMAN CELL; LYMPHOCYTE ACTIVATION; MALE; PHAGOCYTE; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE;

ADOLESCENT; ADULT; AGED; BLAST CRISIS; CELL DIFFERENTIATION; CELLS, CULTURED; DENDRITIC CELLS; DRUG SYNERGISM; FEMALE; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, ACUTE; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; POLY I-C; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; YOUNG ADULT;

EID: 84863990705     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2012.04.007     Document Type: Article

References (43)

1. Estey E., Dohner H. Acute myeloid leukaemia. Lancet 2006, 368(November (9550)):1894-1907.
2. Lowenberg B., Downing J.R., Burnett A. Acute myeloid leukemia. N Engl J Med 1999, 341(14):1051-1062.
3. van den Ancker W., Westers T.M., Ossenkoppele G.J., van de Loosdrecht A.A. Back to basics: in search of the optimal dendritic cell for vaccination in AML. Leuk Res 2008, 32(November (11)):1641-1643.
4. Smith M., Barnett M., Bassan R., Gatta G., Tondini C., Kern W. Adult acute myeloid leukaemia. Crit Rev Oncol Hematol 2004, 50(June (3)):197-222.
5. Draube A., Beyer M., Wolf J. Activation of autologous leukemia-specific T cells in acute myeloid leukemia: monocyte-derived dendritic cells cocultured with leukemic blasts compared with leukemia-derived dendritic cells. Eur J Haematol 2008, 81(October (4)):281-288.
6. Smits E.L., Lee C., Hardwick N., Brooks S., Van Tendeloo V.F., Orchard K., et al. Clinical evaluation of cellular immunotherapy in acute myeloid leukaemia. Cancer Immunol Immunother 2011, 60(June (6)):757-769.
7. Banchereau J., Palucka A.K. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol 2005, 5(April (4)):296-306.
8. Schmitt A., Hus I., Schmitt M. Dendritic cell vaccines for leukemia patients. Expert Rev Anticancer Ther 2007, 7(March (3)):275-283.
9. Westers T.M., Ossenkoppele G.J., van de Loosdrecht A.A. Dendritic cell-based immunotherapy in acute and chronic myeloid leukaemia. Biomed Pharmacother 2007, 61(July (6)):306-314.
10. Schmitt A., Li L., Giannopoulos K., Greiner J., Reinhardt P., Wiesneth M., et al. Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion (Paris) 2008, 48(May (5)):861-870.
11. Grabrucker C., Liepert A., Dreyig J., Kremser A., Kroell T., Freudenreich M., et al. The quality and quantity of leukemia-derived dendritic cells from patients with acute myeloid leukemia and myelodysplastic syndrome are a predictive factor for the lytic potential of dendritic cells-primed leukemia-specific T cells. J Immunother 2010, 33(June (5)):523-537.
12. Houtenbos I., Westers T.M., Ossenkoppele G.J., van de Loosdrecht A.A. Employing the immunological synapse in AML: development of leukemic dendritic cells for active specific immunization. Immunobiology 2005, 210(2-4):249-257.
13. Kufner S., Zitzelsberger H., Kroell T., Pelka-Fleischer R., Salem A., de Valle F., et al. Leukemia-derived dendritic cells can be generated from blood or bone marrow cells from patients with acute myeloid leukaemia: a methodological approach under serum-free culture conditions. Scand J Immunol 2005, 62(July (1)):86-98.
14. van Duin D., Medzhitov R., Shaw A.C. Triggering TLR signaling in vaccination. Trends Immunol 2006, 27(January (1)):49-55.
15. Schreibelt G., Tel J., Sliepen K.H., Benitez-Ribas D., Figdor C.G., Adema G.J., et al. Toll-like receptor expression and function in human dendritic cell subsets: implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010, 59(October (10)):1573-1582.
16. Roses R.E., Xu S., Xu M., Koldovsky U., Koski G., Czerniecki B.J. Differential production of IL-23 and IL-12 by myeloid-derived dendritic cells in response to TLR agonists. J Immunol 2008, 181(October (7)):5120-5127.
17. Spranger S., Javorovic M., Burdek M., Wilde S., Mosetter B., Tippmer S., et al. Generation of Th1-polarizing dendritic cells using the TLR7/8 agonist CL075. J Immunol 2010, 185(July (1)):738-747.
18. Beck B., Dorfel D., Lichtenegger F.S., Geiger C., Lindner L., Merk M., et al. Effects of TLR agonists on maturation and function of 3-day dendritic cells from AML patients in complete remission. J Trans Med 2011, 9:151.
19. van den Ancker W., van Luijn M.M., Ruben J.M., Westers T.M., Bontkes H.J., Ossenkoppele G.J., et al. Targeting Toll-like receptor 7/8 enhances uptake of apoptotic leukemic cells by monocyte-derived dendritic cells but interferes with subsequent cytokine-induced maturation. Cancer Immunol Immunother 2011, 60(January (1)):37-47.
20. Warger T., Osterloh P., Rechtsteiner G., Fassbender M., Heib V., Schmid B., et al. Synergistic activation of dendritic cells by combined Toll-like receptor ligation induces superior CTL responses in vivo. Blood 2006, 108(July (2)):544-550.
21. Bohnenkamp H.R., Papazisis K.T., Burchell J.M., Taylor-Papadimitriou J. Synergism of Toll-like receptor-induced interleukin-12p70 secretion by monocyte-derived dendritic cells is mediated through p38 MAPK and lowers the threshold of T-helper cell type 1 responses. Cell Immunol 2007, 247(June (2)):72-84.
22. Drexler H.G. Classification of acute myeloid leukemias-a comparison of FAB and immunophenotyping. Leukemia 1987, 1(October (10)):697-705.
23. Neame P.B., Soamboonsrup P., Browman G.P., Meyer R.M., Benger A., Wilson W.E., et al. Classifying acute leukemia by immunophenotyping: a combined FAB-immunologic classification of AML. Blood 1986, 68(December (6)):1355-1362.
24. Brugger W., Schneider A., Schammann T., Dill P., Grunebach F., Buhring H.J., et al. Dendritic cell-based vaccines in patients with hematological malignancies. Ann N Y Acad Sci 2001, 938(June):359-362. discussion 62-3.
25. Robinson S.P., English N., Jaju R., Kearney L., Knight S.C., Reid C.D. The in vitro generation of dendritic cells from blast cells in acute leukaemia. Br J Haematol 1998, 103(December (3)):763-771.
26. Kohler T., Plettig R., Wetzstein W., Schmitz M., Ritter M., Mohr B., et al. Cytokine-driven differentiation of blasts from patients with acute myelogenous and lymphoblastic leukemia into dendritic cells. Stem Cells 2000, 18(2):139-147.
27. Brouwer R.E., van der Hoorn M., Kluin-Nelemans H.C., van Zelderen-Bhola S., Willemze R., Falkenburg J.H. The generation of dendritic-like cells with increased allostimulatory function from acute myeloid leukemia cells of various FAB subclasses. Hum Immunol 2000, 61(June (6)):565-574.
28. Danilov S.M., Sadovnikova E., Scharenborg N., Balyasnikova I.V., Svinareva D.A., Semikina E.L., et al. Angiotensin-converting enzyme (CD143) is abundantly expressed by dendritic cells and discriminates human monocyte-derived dendritic cells from acute myeloid leukemia-derived dendritic cells. Exp Hematol 2003, 31(December (12)):1301-1309.
29. Sallusto F., Cella M., Danieli C., Lanzavecchia A. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products. J Exp Med 1995, 182(August (2)):389-400.
30. Berger T.G., Feuerstein B., Strasser E., Hirsch U., Schreiner D., Schuler G., et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods 2002, 268(October (2)):131-140.
31. Royer P.J., Bougras G., Ebstein F., Leveque L., Tanguy-Royer S., Simon T., et al. Efficient monocyte-derived dendritic cell generation in patients with acute myeloid leukemia after chemotherapy treatment: application to active immunotherapy. Exp Hematol 2008, 36(March (3)):329-339.
32. Hsu F.J., Benike C., Fagnoni F., Liles T.M., Czerwinski D., Taidi B., et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med 1996, 2(January (1)):52-58.
33. Bagheri K., Alimoghadam K., Pourfathollah A.A., Hassan Z.M., Hajati J., Moazzeni S.M. The efficient generation of immunocompetent dendritic cells from leukemic blasts in acute myeloid leukemia: a local experience. Pathol Oncol Res 2008, September.
34. Stripecke R., Levine A.M., Pullarkat V., Cardoso A.A. Immunotherapy with acute leukemia cells modified into antigen-presenting cells: ex vivo culture and gene transfer methods. Leukemia 2002, 16(October (10)):1974-1983.
35. Choi B.H., Kang H.K., Park J.S., Kim S.K., Pham T.N., Zhu X.W., et al. Optimization of the concentration of autologous serum for generation of leukemic dendritic cells from acute myeloid leukemic cells for clinical immunotherapy. J Clin Apher 2006, 21(December (4)):233-240.
36. Santiago-Schwarz F., Coppock D.L., Hindenburg A.A., Kern J. Identification of a malignant counterpart of the monocyte-dendritic cell progenitor in an acute myeloid leukemia. Blood 1994, 84(November (9)):3054-3062.
37. Santegoets S.J.S.M., Masterson A.J., Liu Y.P., Goletz S., Baumeister H. In vitro priming of tumor-specific cytotoxic T lymphocytes using allogeneic dendritic cells derived from the human MUTZ-3 cell line. Cancer Immunol Immunother 2006, 55:1480-1490.
38. Li L., Reinhardt P., Schmitt A., Barth T.F., Greiner J., Ringhoffer M., et al. Dendritic cells generated from acute myeloid leukemia (AML) blasts maintain the expression of immunogenic leukemia associated antigens. Cancer Immunol Immunother 2005, 54(July (7)):685-693.
39. Tong X.M., Yao H.P., Qian W.B., Zhu L.F., Fu Z.H., Huang Z.L., et al. The biological characteristics of dendritic cells derived in vitro from myelogeneous leukemia cells and healthy donor cells. Int J Lab Hematol 2008, 30(October (5)):372-381.
40. Kufner S., Fleischer R.P., Kroell T., Schmid C., Zitzelsberger H., Salih H., et al. Serum-free generation and quantification of functionally active leukemia-derived DC is possible from malignant blasts in acute myeloid leukemia and myelodysplastic syndromes. Cancer Immunol Immunother 2005, 54(October (10)):953-970.
41. Westers T.M., Stam A.G., Scheper R.J., Regelink J.C., Nieuwint A.W., Schuurhuis G.J., et al. Rapid generation of antigen-presenting cells from leukaemic blasts in acute myeloid leukaemia. Cancer Immunol Immunother 2003, 52(January (1)):17-27.
42. Kawai T.A.S. Antiviral signaling through pattern recognition receptors. J Biochem 2007, 141:137-145.
43. Zobywalski A., Javorovic M., Frankenberger B., Pohla H., Kremmer E., Bigalke I., et al. Generation of clinical grade dendritic cells with capacity to produce biologically active IL-12p70. J Trans Med 2007, 5:18.